IP Library Granted Patent US 9,399,055
Granted Patent B2
US 9,399,055 · App. 14/336,492 · Granted Jul 26, 2016

Anti-cancer nanoparticle compositions and methods of use

Inventors: Anna Radominska-Pandya (Little Rock, AR); Alexandru S. Biris (Little Rock, AR)
Assignee: Board of Trustees of the University of Arkansas
A61K38/45A61K9/0092A61K31/711A61K38/17A61K47/48853A61K47/48861A61K47/48869A61K47/48884B82Y5/00A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,055
App. No.
14/336,492
Granted
Jul 26, 2016
Kind
B2
Abstract

The present invention encompasses a composition capable of delivering and expressing a nucleic acid encoding UDP-Glucuronosyltransferases, p53 or a combination thereof into a cell, and methods for treating tumors.

Claims (12)

1. An isolated pancreatic tumor cell, wherein the tumor cell comprises at least one nucleic acid attached to a nanoparticle, wherein the at least one nucleic acid is a nucleic acid encoding UGT2B15, and the nanoparticle is selected from the group consisting of a carbon nanotube, carbon nanorod, and carbon nanosphere, such that the nucleic acid is expressed within the pancreatic tumor cell.

2. The composition of claim 1 , wherein the nanotube is selected from the group consisting of a single-wall carbon nanotube, a double-wall carbon nanotube, and a multi-wall carbon nanotube.

3. The composition of claim 1 , wherein the nanoparticle is bio-degradable and/or bio-compatible.

4. The composition of claim 1 , wherein the nucleic acid is attached to the nanoparticle using a method selected from the group consisting of covalent bonding, hydrogen bonding, click attachment, and physical attachment.

5. The composition of claim 1 , wherein the nucleic acid is non-covalently attached.

6. The composition of claim 1 , wherein the composition further comprises a targeting agent.

7. An ex vivo pancreatic tumor cell, wherein the tumor cell comprises at least one nucleic acid attached to a nanoparticle, wherein the at least one nucleic acid is a nucleic acid encoding UGT2B15, and the nanoparticle is selected from the group consisting of a carbon nanotube, carbon nanorod, and carbon nanosphere, such that the nucleic acid is expressed within the pancreatic tumor cell.

8. The composition of claim 7 , wherein the nanotube is selected from the group consisting of a single-wall carbon nanotube, a double-wall carbon nanotube, and a multi-wall carbon nanotube.

9. The composition of claim 7 , wherein the nanoparticle is bio-degradable and/or bio-compatible.

10. The composition of claim 7 , wherein the nucleic acid is attached to the nanoparticle using a method selected from the group consisting of covalent bonding, hydrogen bonding, click attachment, and physical attachment.

11. The composition of claim 7 , wherein the nucleic acid is non-covalently attached.

12. The composition of claim 7 , wherein the composition further comprises a targeting agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2018
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 047667/0515 →
CONFIRMATORY LICENSE Recorded Jun 10, 2016
From: UNIV OF ARKANSAS FOR MED SCIS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038949/0090 →
Continuity (4)
Division 13073270 · Mar 28, 2011
Provisional Application 61446844 · Feb 25, 2011
Provisional Application 61317854 · Mar 26, 2010
Related Publication 20140328927A1 · Nov 6, 2014